PROJECT SUI /11 /IARY (See instructions):
The aim of this proposal is to identify and validate biomarkers that will, for the first time, enable individualization of therapy in ovarian cancer. This proposal will thus include the execution of an innovative phase II clinical trial that will facilitate the validation of novel biomarkers that predict the clinical efficacy of targeted therapies in individual women with ovarian cancer. We will target two biologic processes that we and others have established as playing critical roles in the pathogenesis of epithelial ovarian cancer: (i) activation of the phosphatidylinositide-3-kinase (PISK/AKT/mTOR) pathway ('PISKness'), and (ii) deficient BRCA1/2-mediated homologous recombination (HR) ('BRCAness'). This proposal will build on the successful phase I trial targeting the PISK signaling pathway in ovarian cancer thay we executed in the previous SPORE funding period. It will also build on our new data indicating that somatic mutations and loss of BRCA1 and BRCA2 function are significantly more common than previously thought in ovarian cancer and should predict sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) that exhibit synthetic lethality with BRCA1/2 dysfunction. This proposal will bring together: 1. the SouthWest Oncology Group (SWOG) to facilitate execution of the phase II trial, 2. Astra Zeneca to provide access to the novel therapies olaparib (PARPi) and AZD8055 (PISK pathway inhibitor), and 3. Myriad Genetics, Inc.
The specific aims are:
Aim 1 : A. To determine whether 'PISKness'predicts responsiveness to PISK pathway inhibitors in cell lines and ovarian cancer xenografts. B. To determine whether 'PISKness'predicts outcome in ovarian cancer patients treated with surgery and platinum/paclitaxel-based chemotherapy.
Aim 2; A. To determine whether 'BRCAness'predicts responsiveness to PARP inhibitors in cell lines and ovarian cancer xenografts. B. To determine whether "BRCAness" predicts outcome in ovarian cancer patients treated with surgery and platinum/paclitaxel-based chemotherapy.
Aim S;To determine whether 'PISKness'and 'BRCAness'predict response to targeting the PISK/AKT/mTOR pathway and PARP, respectively, in a phase II ovarian cancer clinical trial.
The successful execution of this study wiil contribute to: 1) the implementation of novel therapies with clinical utility, and 2) progress towards individualization of treatment for women with ovarian cancer. As a result, we expect that the successful execution of this research proposal will lead to improved therapy and outcomes for w/omen with ovarian cancer as well as define paradigms and trial designs that can be applied broadly to increase the rate of successful implementation of targeted therapy in ovarian cancer.
|Bottsford-Miller, Justin; Choi, Hyun-Jin; Dalton, Heather J et al. (2015) Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res 21:602-10|
|Sun, Yan; Hu, Limei; Zheng, Hong et al. (2015) MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 235:25-36|
|Wen, Yunfei; Graybill, Whitney S; Previs, Rebecca A et al. (2015) Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21:448-59|
|Previs, Rebecca A; Coleman, Robert L; Harris, Adrian L et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res 21:955-61|
|Zhang, Shu; Lu, Zhen; Unruh, Anna K et al. (2015) Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res 13:393-401|
|Zhang, Shiwu; Mercado-Uribe, Imelda; Liu, Jinsong (2014) Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. Int J Cancer 134:508-18|
|Matsuo, Koji; Sheridan, Todd B; Mabuchi, Seiji et al. (2014) Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol 133:473-9|
|Liu, Guoyan; Sun, Yan; Ji, Ping et al. (2014) MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol 233:308-18|
|Rich, Thereasa A; Liu, Mei; Etzel, Carol J et al. (2014) Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13:291-9|
|Zhang, S; Mercado-Uribe, I; Xing, Z et al. (2014) Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene 33:116-28|
Showing the most recent 10 out of 381 publications